Renascience Inc.

Renascience Inc. develops and commercializes pharmaceuticals and medical devices in Japan. Its pipeline includes RS5614, a PAI-1 inhibitor candidate for chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angiosarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, a PAI-1 inhibitor in Phase I trials for alopecia; and RS8001, a water-soluble vitamin in Phase 1 trials for premenstrual syndrome/premenstrual dysphoric disorder and menopausal disorder. The company is also developing RS9001, a disposable ultrafine endoscope, as well as artificial intelligence-based medical solutions and diagnostic solutions. Incorporated in 2000, it is headquartered in Sendai, Japan.